Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

INMB

INmune Bio Inc

Dec 11 • 04:00PM ET

5.25

Dollar change -0.19
Percentage change -3.49	%

Healthcare • Biotechnology • USA • NASD

Peers: ABUS SLNO LPTX TNXP ONCY PDSB IMUX PRQR CYCC MEIP

| Held by: VTI IWM VXF IWO VTWO ONEQ IWC VTWG RSSL DFAC

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-2.18	Insider Own	28.90%	Shs Outstand	22.17M	Perf Week	3.96%
Market Cap	116.41M	Forward P/E	-	EPS next Y	-2.04	Insider Trans	0.60%	Shs Float	15.76M	Perf Month	-14.36%
Income	-41.27M	PEG	-	EPS next Q	-0.56	Inst Own	26.83%	Short Float	23.52%	Perf Quarter	-17.84%
Sales	0.04M	P/S	2910.25	EPS this Y	-37.43%	Inst Trans	110.37%	Short Ratio	14.19	Perf Half Y	-40.00%
Book/sh	1.74	P/B	3.01	EPS next Y	10.94%	ROA	-71.48%	Short Interest	3.71M	Perf Year	-48.88%
Cash/sh	1.51	P/C	3.47	EPS next 5Y	-	ROE	-98.97%	52W Range	4.45 - 14.74	Perf YTD	-53.37%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-5.50%	ROI	-105.94%	52W High	-64.38%	Beta	1.77
Dividend TTM	-	Quick Ratio	2.59	Sales past 5Y	321.24%	Gross Margin	-	52W Low	17.98%	ATR (14)	0.35
Dividend Ex-Date	-	Current Ratio	2.59	EPS Y/Y TTM	-42.98%	Oper. Margin	-98921.43%	RSI (14)	50.29	Volatility	6.54% 6.66%
Employees	17	Debt/Eq	0.08	Sales Y/Y TTM	-81.25%	Profit Margin	-98266.67%	Recom	1.33	Target Price	19.83
Option/Short	Yes / Yes	LT Debt/Eq	0.01	EPS Q/Q	-25.99%	Payout	-	Rel Volume	0.76	Prev Close	5.44
Sales Surprise	-100.00%	EPS Surprise	-18.41%	Sales Q/Q	-100.00%	Earnings	Oct 31 AMC	Avg Volume	261.20K	Price	5.25
SMA20	4.06%	SMA50	-1.81%	SMA200	-34.76%	Trades		Volume	198,746	Change	-3.49%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-21-24	Initiated	Alliance Global Partners	Buy	$20
Sep-27-24	Initiated	Raymond James	Outperform	$18
Aug-22-24	Initiated	Scotiabank	Sector Outperform	$22
Jun-01-23	Initiated	Robert W. Baird	Outperform	$16
May-24-22	Downgrade	B. Riley Securities	Buy → Neutral	$14 → $7
Jul-07-21	Reiterated	Maxim Group	Buy	$32 → $42
Apr-21-21	Initiated	B. Riley Securities	Buy	$29
Jan-22-21	Reiterated	Maxim Group	Buy	$16 → $32
Sep-01-20	Initiated	BTIG Research	Buy	$23
Jul-15-20	Reiterated	H.C. Wainwright	Buy	$7 → $20

Dec-10-24 08:00AM	INmune Bio Inc. Completes Repayment of Silicon Valley Bank Debt (GlobeNewswire)
Dec-04-24 02:51PM	OmniScience and INmune Bio Partner for Alzheimers Trial (Exec Edge)
09:00AM	OmniScience Inc. and INmune Bio Inc. Partner to Accelerate a Phase 2 Alzheimer's Trial with Vivo, a Novel genAI Clinical Trial Control Tower (Business Wire)
Nov-13-24 09:00AM	INmune Bio Inc. Announces Final Enrollment of 208 Patients in Phase 2 Trial in Early Alzheimer's Disease (GlobeNewswire)
Nov-01-24 11:01AM	INmune Bio Inc (INMB) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges and ... (GuruFocus.com)
04:05PM	Loading…
Oct-31-24 04:05PM	INmune Bio Inc. Announces Third Quarter 2024 Results and Provides Business Update (GlobeNewswire)
Oct-30-24 09:22AM	INmune Bio Inc (INMB) Q3 2024 Earnings Report Preview: What To Look For (GuruFocus.com) -5.56%
Oct-28-24 08:00AM	INmune Bio Inc. to Host Webinar on Cognitive Testing Using EMACC and CDR-SB (GlobeNewswire) +13.75%
Oct-25-24 01:02PM	Highbridge Capital Management's Strategic Acquisition of INmune Bio Inc Shares (GuruFocus.com)
Oct-24-24 03:03PM	INmune Bio Inc. Announces Publication in Cell Reports Demonstrating XPro Promotes Remyelination (GlobeNewswire)
09:30AM	INmune Bio Inc. to Report Third Quarter 2024 Financial Results and Provide Corporate Update on October 31, 2024 (GlobeNewswire)
Oct-11-24 08:30AM	INmune Bio Inc. to Participate in the Maxim Healthcare Virtual Summit (GlobeNewswire)
Oct-09-24 03:51PM	INmune Bio Inc (INMB) Q2 2024 Earnings Call Highlights: Promising Advances Amid Rising Costs (GuruFocus.com)
Sep-30-24 08:00AM	INmune Bio Inc. Completes Enrollment for Phase 2 Trial in Early Alzheimer's Disease (GlobeNewswire)
Sep-26-24 08:00AM	INKmune Demonstrates Excellent Safety and Increased NK-Cell Activity in First Dosing Cohort (GlobeNewswire)
08:30AM	Loading…
Sep-17-24 08:30AM	INmune Bio Announces Results of Additional Blinded Interim Analysis of Phase 2 Alzheimer's Disease Trial Demonstrating Correlation between EMACC and CDR-SB Endpoints (GlobeNewswire)
Sep-13-24 08:30AM	INmune Bio Announces $13.0 Million Registered Direct Offering (GlobeNewswire) -14.55%
Sep-03-24 09:00AM	INmune Bio Inc. to Present at the Baird 2024 Global Healthcare Conference (GlobeNewswire) -7.10%
Aug-01-24 04:05PM	INmune Bio Inc. Announces Second Quarter 2024 Results and Provides Business Update (GlobeNewswire) -7.92%
Jul-29-24 09:00AM	INmune Bio Inc. Announces New Phase 1 Study Data Demonstrating Dose-Dependent Effect of XPro on Proteins that Regulation Synapses in Alzheimer's Patients (GlobeNewswire)
Jul-25-24 08:00AM	INmune Bio Inc. to Report Second Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, August 1, 2024 (GlobeNewswire)
Jul-23-24 08:45AM	INmune Bio Inc. Publishes Novel Biology on Natural Killer Cancer Immunotherapy INKmune in the Journal for ImmunoTherapy of Cancer (GlobeNewswire)
Jun-28-24 12:13PM	INmune Bios unique Alzheimers trial endpoint receives validation (Clinical Trials Arena)
Jun-27-24 08:00AM	INmune Bio, Inc. Completes Blinded Interim Analysis of Phase II Alzheimer's Disease Trial (GlobeNewswire) +19.20%
May-30-24 08:00AM	INmune Bio Inc. to Join Russell 3000 Index (GlobeNewswire)
May-13-24 11:54AM	INmune Bio, Inc. (NASDAQ:INMB) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-09-24 04:05PM	INmune Bio Inc. Announces First Quarter 2024 Results and Provides Business Update (GlobeNewswire) -6.96%
May-07-24 08:00AM	INmune Bio Inc. to Report First Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, May 9 (GlobeNewswire)
Apr-30-24 08:00AM	INmune Bio Inc. Provides Update on Two Patients from the Phase 1b Alzheimer's Disease Trial who Continue to Receive XPro Under Compassionate Use for Over Three Years (GlobeNewswire)
Apr-29-24 08:00AM	INmune Bio Inc. Completes First Cohort and Initiates Second Cohort of Phase 1/2 Study of INKmune Natural Killer Cell Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer (GlobeNewswire)
09:00AM	Loading…
Apr-25-24 09:00AM	INmune Bio Inc. Announces $9.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire)
Apr-23-24 08:00AM	INmune Bio Inc. Announces 24-Month Stability Validation of XPro for Phase III Readiness and Commercial Supply Chain Modeling & Development of Novel Immunogenicity Assay (GlobeNewswire)
Apr-22-24 08:00AM	INmune Bio Inc. Raises Approximately $4.8 Million in Gross Proceeds Through Registered Direct Offering with Officers, Employees and Directors Purchasing Approximately 20% of the Offering (GlobeNewswire) +26.94%
Apr-08-24 08:00AM	INmune Bio Inc. Presents Data on INB03's Role as an Immune Check Point Modulator in the Treatment of High-Risk Breast Cancer at AACR 2024 (GlobeNewswire)
Apr-01-24 10:20AM	INmune Bio, Inc. (NASDAQ:INMB) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-29-24 05:31PM	INmune Bio Inc (INMB) Posts Year-End Earnings, Reveals Net Loss Amidst Clinical Advancements (GuruFocus.com)
Mar-28-24 08:53PM	INMB Stock Earnings: INmune Bio Misses EPS, Misses Revenue for Q4 2023 (InvestorPlace)
04:01PM	INmune Bio Inc. Announces Year End 2023 Results and Provides a Q4 Business Update (GlobeNewswire)
Mar-26-24 04:01PM	INmune Bio Inc. to Report Fourth Quarter 2023 Financial Results and Provide a Corporate Update on Thursday, March 28 (GlobeNewswire)
Mar-13-24 08:00AM	INmune Bio CSO and Co-Founder Mark Lowdell, Ph.D. Receives The ISCT Career Achievement Award in Cell and Gene Therapy (GlobeNewswire)
Mar-05-24 08:00AM	INmune Bio Reports Significant EEG Improvement in Alzheimer's Patients Treated with XPro (GlobeNewswire) -5.37%
Feb-12-24 09:00AM	INmune Bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Feb-06-24 09:00AM	INmune Bio to Participate in Baird's Biotech Discovery Series Webcast on February 13, 2024 (GlobeNewswire)
Jan-30-24 08:00AM	INmune Bio Announces FDA Removal of Clinical Hold for Alzheimer's Disease Program (GlobeNewswire) -7.52%
Jan-16-24 08:30AM	ELEVAI Labs, Inc. Acquires Worldwide License Agreement for Proprietary Stem Cell Manufacturing Technology (GlobeNewswire) -6.72%
Jan-02-24 08:00AM	INmune Bio Announces First Patient Dosed in a Phase 1/2 Study of INKmune in Patients with Metastatic Castration-Resistant Prostate Cancer (GlobeNewswire)
Dec-18-23 04:01PM	INmune Bio Provides Update Regarding Global Alzheimer's Phase II Clinical Trial and Clinical Hold Issued by the United States FDA (GlobeNewswire) +7.97% -9.29%
Nov-29-23 08:35AM	Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks (Investor's Business Daily)
08:00AM	INmune Bio Inc. Demonstrates that INB03 Enhances the Uptake of Trastuzumab Deruxtecan in HER2+ Breast Cancer with MUC4 Expression in Poster Presented at San Antonio Breast Cancer Symposium (GlobeNewswire)
Nov-27-23 08:00AM	INmune Bio Receives EMA's Authorization in France and Spain for Phase II Clinical Trial of XPro for Early Alzheimer's Disease (GlobeNewswire)
Nov-17-23 08:15AM	Quest For Alzheimer's Cure: Big Biotech Breakthroughs, But The Race Is Just Beginning (Investor's Business Daily)
Nov-15-23 09:00AM	INmune Bio Inc. Announces Expansion of Phase II Clinical Trial for Alzheimer's Disease in Europe (GlobeNewswire)
Nov-02-23 10:11AM	INmune Bio, Inc. (NASDAQ:INMB) Q3 2023 Earnings Call Transcript (Insider Monkey)
09:54AM	Q3 2023 INmune Bio Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-01-23 06:44PM	INmune Bio Inc (INMB) Reports Q3 2023 Financial Results (GuruFocus.com)
04:10PM	INmune Bio Inc. Announces Third Quarter 2023 Results and Provides Business Update (GlobeNewswire)
Oct-31-23 08:00AM	INmune Bio Inc. Patent Claims Covering INB16 Cell Line and INKmune Therapeutic Composition given Favorable Patentability Opinion by International Search Authority (GlobeNewswire) +7.84%
Oct-30-23 09:07AM	INmune Bio Inc. Presents Preclinical Data at SITC 2023 Showing INB03 is an Innate Immune Check Point Inhibitor that Downregulates SIRP (GlobeNewswire)
Oct-25-23 09:00AM	Cumulus Neuroscience Presents Data at CTAD 2023 Annual Meeting (PR Newswire)
Oct-17-23 08:00AM	INmune Bio Inc. Presents New Biomarker and Feasibility Data from Phase 1b Study Supporting the Use of XPro to Treat Alzheimer's Disease at Clinical Trials on Alzheimer's Disease (CTAD) Conference (GlobeNewswire) +10.32%
Oct-16-23 09:00AM	INmune Bio Inc. to Report Third Quarter 2023 Financial Results and Provide a Corporate Update on Wednesday, November 1 (GlobeNewswire)
Sep-07-23 09:00AM	INmune Bio Inc. to Present at Baird Global Healthcare Conference and H.C Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Sep-05-23 08:00AM	INmune Bio Inc. Announces Approval of Clinical Trial Application by the U.K. Medicines and Healthcare Products Regulatory Agency for Phase 2 Clinical Trial in Alzheimers Disease (GlobeNewswire)
Aug-28-23 10:22AM	15 Most Shorted Stocks That Are Loved By Analysts (Insider Monkey) -5.82%
Aug-08-23 09:07AM	INmune Bio, Inc. (NASDAQ:INMB) Q2 2023 Earnings Call Transcript (Insider Monkey) -10.39%
06:33AM	Q2 2023 INmune Bio Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-07-23 04:00PM	INmune Bio Inc. Announces Second Quarter 2023 Results and Provides Business Update (GlobeNewswire)
Aug-01-23 08:00AM	INmune Bio Inc. to Present at the BTIG Virtual Biotechnology Conference (GlobeNewswire)
Jul-31-23 08:00AM	INmune Bio, Inc. to Report Second Quarter 2023 Financial Results and Provide a Corporate Update on Monday, August 7 (GlobeNewswire)
Jul-12-23 08:00AM	INmune Bio Inc. to Deliver Keynote Talk at 5th World Aging and Rejuvenation Conference. (GlobeNewswire) -6.94%
Jul-11-23 08:00AM	INmune Bio Inc. Announces Novel MRI Biomarker Data Demonstrating Improvement in Gray Matter in Patients with Alzheimers Disease (GlobeNewswire) +14.16%
Jul-10-23 04:00PM	INmune Bio Inc. Announces Data Presented at the 16th European Meeting on Glial Cells in Health and Disease Shows that XPro Promotes Remyelination by Affecting Astroglial and Microglial Biology (GlobeNewswire)
May-24-23 09:00AM	INmune Bio Inc.s Chief Scientific Officer, Mark Lowdell, Ph.D. to Present Plenary Talk at International Society of Cell & Gene Therapy (GlobeNewswire)
May-08-23 08:00AM	INmune Bio, Inc. Announces FDA Clearance of IND Application for INKmune, a Natural Killer Therapy, for a Phase I/II Trial in Metastatic Castration-Resistant Prostate Cancer (GlobeNewswire)
May-05-23 06:15AM	INmune Bio First Quarter 2023 Earnings: US$0.36 loss per share (vs US$0.39 loss in 1Q 2022) (Simply Wall St.) +6.61%
May-04-23 08:13AM	Q1 2023 INmune Bio Inc Earnings Call (Thomson Reuters StreetEvents)
May-03-23 04:10PM	INmune Bio Inc. Announces First Quarter 2023 Results and Provides Business Update (GlobeNewswire) -5.60%
Apr-30-23 08:34AM	A number of insiders bought INmune Bio, Inc. (NASDAQ:INMB) stock last year, which is great news for shareholders (Simply Wall St.)
Apr-24-23 09:00AM	INmune Bio, Inc. to Report First Quarter 2023 Financial Results and Provide a Corporate Update on Wednesday, May 3 (GlobeNewswire)
Apr-19-23 08:30AM	XPro1595 Improves Outcomes in a Mouse Model of TBI-induced Alzheimers Disease (GlobeNewswire)
Apr-11-23 08:00AM	INmune Bio, Inc. to Present Preclinical Data at the 2023 AACR Annual Meeting Showing Improved Outcomes in High-Risk Breast Cancer by Targeting MUC4 Expression with INB03 (GlobeNewswire) +6.67%
Apr-03-23 09:00AM	INmune Bio, Inc. Announces Submission of Investigational New Drug (IND) Application for INKmune to the U.S. Food and Drug Administration for Treatment of Metastatic Castration-Resistant Prostate Cancer (GlobeNewswire) +6.97%
Mar-20-23 06:46AM	INmune Bio, Inc.'s (NASDAQ:INMB) top owners are retail investors with 55% stake, while 25% is held by insiders (Simply Wall St.) -5.78%
Mar-06-23 09:48AM	INmune Bio, Inc. (NASDAQ:INMB) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-03-23 09:53AM	Q4 2022 INmune Bio Inc Earnings Call (Thomson Reuters StreetEvents) -7.31%
Mar-02-23 04:05PM	INmune Bio, Inc. Announces 2022 Results and Provides Business Update (GlobeNewswire)
Feb-21-23 09:00AM	INmune Bio, Inc. to Report Fourth Quarter and Full-Year 2022 Results and Provide a Corporate Update on Thursday, March 2 (GlobeNewswire)
Feb-08-23 08:45AM	INmune Bio, Inc. Receives Approximately $6.4 Million in Research and Development Rebates from Australia and the United Kingdom (GlobeNewswire) +10.05%
Jan-25-23 07:45AM	INmune Bio, Inc. Announces Pre-Clinical Data That Support a Pioneering Approach to Treating Duchenne Muscular Dystrophy (GlobeNewswire) +9.33%
Dec-22-22 08:00AM	INmune Bio, Inc., Virginia Commonwealth University, and Barrow Neurological Institute Receive Department of Defense Funding to Study the Role of Traumatic Brain Injury in the Development of Alzheimers Disease (GlobeNewswire)
Dec-21-22 09:55AM	Wall Street Analysts Predict a 99% Upside in INmune Bio, Inc. (INMB): Here's What You Should Know (Zacks)
Dec-08-22 08:00AM	INmune Bio, Inc. Data at ASH Highlight Innovative Natural Killer Cell Therapeutic Platform Showing 100+ Day Persistence of Cancer Killing Memory Like NK Cells in Patients with AML/MDS Following Treatment with INKmune (GlobeNewswire) +6.56%
Dec-06-22 04:00PM	INmune Bio, Inc. Reports Combination Therapy with INB03 Overcomes Resistance to Trastuzumab-Deruxtecan in MUC4 expressing HER2+ Breast Cancer (GlobeNewswire)
Nov-29-22 08:00AM	INmune Bio, Inc. Focused on Novel Clinical Trial Designs to Advance Next Generation of Alzheimers Disease Treatments (GlobeNewswire)
Nov-20-22 07:34AM	Quite a few insiders invested in INmune Bio, Inc. (NASDAQ:INMB) last year which is positive news for shareholders (Simply Wall St.)
Nov-14-22 09:00AM	INmune Bio, Inc. Receives Health Canada No Objection Letter to Commence Clinical Trial of XPro1595 in Mild Alzheimers Disease (GlobeNewswire)
Nov-02-22 04:00PM	INmune Bio, Inc. Announces Third Quarter 2022 Results and Provides Business Update (GlobeNewswire) -6.96%
Oct-26-22 08:10AM	INmune Bio, Inc. to Report Third Quarter 2022 Financial Results and Provide a Corporate Update on Wednesday, November 2 (GlobeNewswire)
Oct-19-22 11:48AM	INmune Bio's INKmune Shows Positive Efficacy In Multiple Cancer Cell Lines (Benzinga)
08:00AM	INmune Bio, Inc. Announces Positive Solid Tumor Efficacy Data in Multiple Cancer Cell Lines for INKmune (GlobeNewswire)

INmune Bio, Inc. Is a clinical stage biotechnology company, which engages in developing new immunotherapies that reprograms the immune system to fight cancer and Alzheimer's disease. Its products include pipeline, INKMUNE-Cancer, INB03-Cancer, XPRO1595-Alzheimer and TRD, and LIVNate. The company was founded by Mark Lowdell in September 2015 and is headquartered in Boca Raton, FL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Moss David J	Chief Financial Officer	Sep 30 '24	Buy	5.29	10,000	52,868	1,285,869	Sep 30 04:01 PM
Tesi Raymond Joseph	President and CEO	Sep 12 '24	Buy	6.38	15,380	98,048	1,554,106	Sep 16 08:48 PM
Moss David J	Chief Financial Officer	Sep 12 '24	Buy	6.38	7,690	49,024	1,275,869	Sep 16 08:47 PM
Juda Scott	Director	Jun 25 '24	Buy	7.27	5,000	36,350	71,603	Jun 26 08:00 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

INMB

INmune Bio Inc

Upgrade your FINVIZ experience